EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...
EpiVax Awarded Grant For Vaccine Engineering

EpiVax Awarded Grant For Vaccine Engineering

$5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX   PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today...
Westin Seminar 2017 (Tokyo)

Westin Seminar 2017 (Tokyo)

[Updated] View Event Photos! The Westin Immunogenicity Seminar is a unique forum for industry and academic professionals to share ideas, present research updates and network with potential collaborators.  The purpose of this seminar is to bridge the gap...